A Strangle Strategy
A (Agilent Technologies, Inc.), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NYSE.
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions.
A (Agilent Technologies, Inc.) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $38.41B, a trailing P/E of 27.22, a beta of 1.26 versus the broader market, a 52-week range of 108.35-160.27, average daily share volume of 2.3M, a public-listing history dating back to 1999, approximately 18K full-time employees. These structural characteristics shape how A stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.26 places A roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. A pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a strangle on A?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current A snapshot
As of June 29, 2026, spot at $132.97, ATM IV 30.10%, IV rank 31.59%, expected move 8.63%. The strangle on A below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this strangle structure on A specifically: A IV at 30.10% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 8.63% (roughly $11.47 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated A expiries trade a higher absolute premium for lower per-day decay. Position sizing on A should anchor to the underlying notional of $132.97 per share and to the trader's directional view on A stock.
A strangle setup
The A strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With A near $132.97, the first option leg uses a $140.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed A chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 A shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $140.00 | $1.10 |
| Buy 1 | Put | $125.00 | $1.00 |
A strangle risk and reward
- Net Premium / Debit
- -$210.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$210.00
- Breakeven(s)
- $122.90, $142.10
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
A strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on A. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$12,289.00 |
| $29.41 | -77.9% | +$9,349.07 |
| $58.81 | -55.8% | +$6,409.14 |
| $88.21 | -33.7% | +$3,469.21 |
| $117.61 | -11.6% | +$529.28 |
| $147.01 | +10.6% | +$490.65 |
| $176.41 | +32.7% | +$3,430.58 |
| $205.81 | +54.8% | +$6,370.51 |
| $235.20 | +76.9% | +$9,310.44 |
| $264.60 | +99.0% | +$12,250.37 |
When traders use strangle on A
Strangles on A are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the A chain.
A thesis for this strangle
The market-implied 1-standard-deviation range for A extends from approximately $121.50 on the downside to $144.44 on the upside. A A long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current A IV rank near 31.59% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on A should anchor more to the directional view and the expected-move geometry. As a Healthcare name, A options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to A-specific events.
A strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. A positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move A alongside the broader basket even when A-specific fundamentals are unchanged. Always rebuild the position from current A chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on A?
- A strangle on A is the strangle strategy applied to A (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With A stock trading near $132.97, the strikes shown on this page are snapped to the nearest listed A chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are A strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the A strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 30.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$210.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a A strangle?
- The breakeven for the A strangle priced on this page is roughly $122.90 and $142.10 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current A market-implied 1-standard-deviation expected move is approximately 8.63%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on A?
- Strangles on A are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the A chain.
- How does current A implied volatility affect this strangle?
- A ATM IV is at 30.10% with IV rank near 31.59%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.